The pharmacodynamics of antiplatelet compounds in thrombosis treatment

References

• Vane JR, Botting M. Aspirin and other salicylates. London: Chapman & Hall Medical; 1992; p. 548–575.
   Google Scholar
• Mellion BT, Ignarro LJ, Ohlstein EH, et al. Evidence for the inhibitory role of guanosine 3¢, 5¢-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood. 1981;57:946–955.
   PubMed Web of Science ®Google Scholar
• Radomski MW, Palmer RM, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol. 1987;92:181–187.
   PubMed Web of Science ®Google Scholar
• Chirkov YY, Horowitz JD. Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier? Pharmacol Ther. 2007;116:287–305.
   PubMed Web of Science ®Google Scholar
• vanGeet C, Izzi B, Labarque V, et al. Human platelet pathology related to defects in the G-protein signaling cascade. J Thromb Haemost. 2009;7(Suppl. 1):282–286.
   PubMed Web of Science ®Google Scholar
• Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010;9:959–968.
   PubMed Web of Science ®Google Scholar
• Rukoyatkina N, Walter U, Friebe A, et al. Differentiation of cGMP-dependent and -independent nitric oxide effects on platelet apoptosis and reactive oxygen species production using platelets lacking soluble guanylyl cyclase. Thromb Haemost. 2011;106:922–933.
   PubMed Web of Science ®Google Scholar
• Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol. 2001;62:1153–1561.
   PubMed Web of Science ®Google Scholar
• Awtry EA, Loscalzo J. Cardiovascular drugs – aspirin. Circulation. 2000;101:1206–1218.
   PubMed Web of Science ®Google Scholar
• Patrono C, Coller B, FitzGerald GA, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:234–264.
   PubMed Web of Science ®Google Scholar
• Palomo I, Toro C, Alarcón M. The role of platelets in the pathophysiology of atherosclerosis (Review). Mol Med Rep. 2008;1(2):179–184.
   PubMed Web of Science ®Google Scholar
• Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res. 2007;100(9):1261–1275.
   PubMed Web of Science ®Google Scholar
• Alli O, Smith C, Hoffman M, et al. Incidence, predictors, and outcomes of gastrointestinal bleeding in patients on dual antiplatelet therapy with aspirin and clopidogrel. J Clin Gastroenterol. 2011;45(5):410–414.
   PubMed Web of Science ®Google Scholar
• Beijing institute of pharmaceutical industry. Research on the active ingredients of Ligustrium wallichii franchat. III. Clinical (218 cases) use of ligustrazine in the treatment of hypoxemic cerebral vascular diseases. Chin Med J. 1997;8:467–469.
   Google Scholar
• Liu SY, Sylvester DM. Antithrombotic/antiplatelet activity of tetramethylpyrazine. Thromb Res. 1990;58:129–140.
   PubMed Web of Science ®Google Scholar
• Ho WKK, Wen HL, Lee CM. Tetramethylpyrazine for treatment of experimentally induced stroke in Mongolian gerbils. Stroke. 1989;20:96–99.
   PubMed Web of Science ®Google Scholar
• Sheu JR, Kan YC, Hung WC, et al. Mechanisms involved in the antiplatelet activity of tetramethylpyrazine in human platelets. Thromb Res. 1997;88:259–270.
   PubMed Web of Science ®Google Scholar
• Feng J, Li F, Zhao Y, et al. Brain pharmacokinetics of tetramethylpyrazine after intranasal and intravenous administration in awake rats. Int J Pharm. 2009;375(1–2):55–60.
   PubMed Web of Science ®Google Scholar
• Huang X, Ren P, Wen AD, et al. Pharmacokinetics of traditional Chinese syndrome and recipe: a hypothesis and its verification (I). World J Gastroenterol. 2000;6(3):384–391.
   PubMed Web of Science ®Google Scholar
• Meng D, Lu H, Huang S, et al. Comparative pharmacokinetics of tetramethylpyrazine phosphate in rat plasma and extracellular fluid of brain after intranasal, intragastric and intravenous administration. Acta Pharm Sin B. 2014;4(1):74–78.
   PubMedGoogle Scholar
• Miller CO, Skoog F, Von Saltza MH, et al. Kinetin, a cell division factor from deoxyribonucleic acid. J Am ChemSoc. 1955;77:1392.
   Web of Science ®Google Scholar
• Minorsky PV. Kinetin: the elixir of life? Plant Physiol. 2003;132:1135–1136.
   Web of Science ®Google Scholar
• Hsiao G, Shen MY, Lin KH, et al. Inhibitory activity of kinetin on free radical formation of activated platelets in vitro and on thrombus formation in vivo. Eur J Pharmacol. 2003;465(3):281–287.
   PubMed Web of Science ®Google Scholar
• Sheu JR, Teng CM, Huang TF. Triflavin, an RGD containing antiplatelet peptide, binds to GP IIIa of ADP stimulated platelets. Biochem Biophys Res Commun. 1992;189:1236–1242.
   PubMed Web of Science ®Google Scholar
• Griffaut B, Bos R, Maurizis JC, et al. Cytotoxic effects of kinetin riboside on mouse, human and plant tumor cells. Int J Biol Macromol. 2004;34(4):271–275.
   PubMed Web of Science ®Google Scholar
• Sheu JR, Lee CR, Lin CC, et al. The antiplatelet activity of PMC, a potent R-tocopherol analogue, is mediated through inhibition of cyclo-oxygenase. Br J Pharmacol. 1999;127:1206–1212.
   PubMed Web of Science ®Google Scholar
• Nagasawa T, Tabata N, Ito Y, et al. Dietary G-rutin suppresses glycation in tissue proteins of streptozotocin-induced diabetic rats. Mol Cell Biochem. 2003;252:141–147.
   PubMed Web of Science ®Google Scholar
• Sheu JR, Lin CH, Peng CH, et al. Triflavin, an Arg-Gly-Asp-containing peptide, inhibits the adhesion of tumor cells to matrix proteins via binding to multiple integrin receptors expressed on human hepatoma cells. Proc Soc Exp Biol Med. 1996;213:71–79.
   PubMed Web of Science ®Google Scholar
• Chen WM, Jin M, Wu W. Experimental study on inhibitory effect of rutin against platelet activation induced by platelet activating factor in rabbits. Zhongguo Zhong Xi Yi Jie He ZaZhi. 2002;22(4):283–285.
   PubMedGoogle Scholar
• Choi JH, Kim DW, Park SE, et al. Anti-thrombotic effect of rutin isolated from Dendropanaxmorbifera Leveille. J Biosci Bioeng. 2015;120(2):181–186.
   PubMed Web of Science ®Google Scholar
• Sheu JR, Hsiao G, Chou PH, et al. Mechanisms involved in the antiplatelet activity of rutin, a glycoside of the flavonol quercetin, in human platelets. J Agric Food Chem. 2004;52(14):4414–4418.
   PubMed Web of Science ®Google Scholar
• Cermak R, Wolffram S. Comment on lymphatic absorption of quercetin and rutin in rat and their pharmacokinetics in systemic plasma. J Agric Food Chem. 2010;58(1):546–551.
   PubMed Web of Science ®Google Scholar
• Voutilainen S, Nurmi T, Mursu J, et al. Carotenoids and cardiovascular health. Am J Clin Nutr. 2006;83:1265–1271.
   PubMed Web of Science ®Google Scholar
• Maiani G, Periago Castón MJ, Catasta G, et al. Carotenoids: actual knowledge on food sources, intakes, stability and bioavailability and their protective role in humans. Mol Nutr Food Res. 2009;53:194–218.
   PubMed Web of Science ®Google Scholar
• Stahl W, Sies H. Antioxidant activity of carotenoids. Mol Aspects Med. 2003;24:345–351.
   PubMed Web of Science ®Google Scholar
• Bosland M, Özten-Kandas N. Chemoprevention of prostate cancer: natural compounds, antiandrogens, and antioxidants - In vivo evidence. J Carcinog. 2011;10:27.
   PubMedGoogle Scholar
• Sonmez M, Turk G, Ceribasi AO, et al. Attenuating effect of lycopeneandellagic acid on 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced spermiotoxic-ity and testicular apoptosis. Drug ChemToxicol. 2011;34:347–356.
   Google Scholar
• Dahan K, Fennal M, Kumar NB. Lycopene in the prevention of prostate cancer. J Soc Integr Oncol. 2008;6:29–36.
   PubMedGoogle Scholar
• Hsiao G, Wang Y, Tzu NH, et al. Inhibitory effects of lycopene on in vitro platelet activation and in vivo prevention of thrombus formation. J Lab Clin Med. 2005;146(4):216–226.
   PubMed Web of Science ®Google Scholar
• Sheu JR, Lee CR, Hsiao G, et al. Comparison of the relative activities of α-tocopherol and PMC on platelet aggregation and antioxidative activity. Life Sci. 1999;65:197–206.
   PubMed Web of Science ®Google Scholar
• Faisal W, O’Driscoll CM, Griffin BT. Bioavailability of lycopene in the rat: the role of intestinal lymphatic transport. J Pharm Pharmacol. 2010;62(3):323–331.
   PubMed Web of Science ®Google Scholar
• Romay C, González R, Ledón N, et al. CPhycocyanin: a biliprotein with antioxidant, anti-inflammatory and neuroprotective effects. Curr Protein Pept Sci. 2003;4:207–216.
   PubMed Web of Science ®Google Scholar
• Romay C, Delgado R, Remirez D, et al. Effects of phycocyanin extract on tumor necrosis factor-alpha and nitrite levels in serum of mice treated with endotoxin. Arzneimittel-Forschung. 2001;51:733–736.
   PubMed Web of Science ®Google Scholar
• Chiu HF, Yang SP, Kuo YL, et al. Mechanisms involved in the antiplatelet effect of C-phycocyanin. Br J Nutr. 2006;95(2):435–440.
   PubMed Web of Science ®Google Scholar
• Hsiao G, Chou PH, Shen MY, et al. C-phycocyanin, a very potent and novel platelet aggregation inhibitor from Spirulina platensis. J Agric Food Chem. 2005;53(20):7734–7740.
   PubMed Web of Science ®Google Scholar
• Akyol S, Ozturk G, Ginis Z, et al. In vivo and in vitro antineoplastic actions of caffeic acid phenethyl ester (CAPE): therapeutic perspectives. Nutr Cancer. 2013;65:515–526.
   PubMed Web of Science ®Google Scholar
• Hsiao G, Lee JJ, Lin KH, et al. Characterization of a novel and potent collagen antagonist, caffeic acid phenethyl ester, in human platelets: in vitro and in vivo studies. Cardiovasc Res. 2007;75(4):782–792.
   PubMed Web of Science ®Google Scholar
• Li Z, Xi X, Gu M, et al. A stimulatory role for cGMP-dependent protein kinase in platelet activation. Cell. 2003;112:77–86.
   PubMed Web of Science ®Google Scholar
• Rosado JA, Sage SO. The ERK cascade, a new pathway involved in the activation of store-mediated calcium entry in human platelets. Trends Cardiovasc Med. 2002;12:229–234.
   PubMed Web of Science ®Google Scholar
• Hughes PE, Renshaw MW, Pfaff M, et al. Suppression of integrin activation: a novel function of a Ras/ Raf-initiated MAP kinase pathway. Cell. 1997;88:521–530.
   PubMed Web of Science ®Google Scholar
• Saklatvala J, Rawlinson L, Waller RJ, et al. Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue. J Biol Chem. 1996;271:6586–6589.
   PubMed Web of Science ®Google Scholar
• Coulon L, Calzada C, Moulin P, et al. Activation of p38 mitogen-activated protein kinase/cytosolic phospholipase A2 cascade in hydroperoxide-stressed platelets. Free Radic Biol Med. 2003;35:616–625.
   PubMed Web of Science ®Google Scholar
• Franke TF, Yang SI, Chan TO, et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell. 1995;81:727–736.
   PubMed Web of Science ®Google Scholar
• Iuliano L, Colavita AR, Leo R, et al. Oxygen free radicals and platelet activation. Free Radic Biol Med. 1997;22:999–1006.
   PubMed Web of Science ®Google Scholar
• Leo R, Ghiselli A, Iuliano L, et al. Detection of hydroxyl radicals by the salicylate bis-hydroxylation during arachidonic acid-dependent platelet activation. Thromb Haemost. 1995;73:A347.
   Web of Science ®Google Scholar
• Waldmann R, Nieberding M, Walter U. Vasodilator-stimulated protein phosphorylation in platelets is mediated by cAMP- and cGMP-dependent protein kinases. Eur J Biochem. 1987;167:441–448.
   PubMedGoogle Scholar
• Halbrügge M, Walter U. Purification of a vasodilator-regulated phosphoprotein from human platelets. Eur J Biochem. 1989;185:41–50.
   PubMedGoogle Scholar
• Chen TG, Lee JJ, Lin KH, et al. Antiplatelet activity of caffeic acid phenethyl ester is mediated through a cyclic GMP-dependent pathway in human platelets. Chin J Physiol. 2007;50(3):121–126.
   PubMed Web of Science ®Google Scholar
• Wang X, Pang J, Maffucci JA, et al. Pharmacokinetics of caffeic acid phenethyl ester and its catechol-ring fluorinated derivative following intravenous administration to rats. Biopharm Drug Dispos. 2009;30(5):221–228.
   PubMed Web of Science ®Google Scholar
• Catalgo BS, Batirel Y, Taga NK. Ozer Resveratrol: French paradox revisited Front. Pharmacol. 2012;3:141.
   Web of Science ®Google Scholar
• Göçmen AY, Burgucu D, Gümüşlü S. Effect of resveratrol on platelet activation in hypercholesterolemic rats: CD40-CD40L system as a potential target. Appl Physiol Nutr Metab. 2011;36(3):323–330.
   PubMed Web of Science ®Google Scholar
• Malinowska J, Olas B. Response of blood platelets to resveratrol during a model of hyperhomocysteinemia. Platelets. 2011;22(4):277–283.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang X, Zhang L, et al. Inhibitory effects of resveratrol on platelet activation induced by thromboxane A(2) receptor agonist in human platelets. Am J Chin Med. 2011;39(1):145–159.
   PubMed Web of Science ®Google Scholar
• Yang YM, Wang XX, Wang SJ, et al. Suppressive effect in vitro of resveratrol on ADP induced human platelet aggregation and its active mechanism. Yao Xue Xue Bao. 2008;43(4):356–360.
   PubMedGoogle Scholar
• Wu CC, Wu CI, Wang WY, et al. Low concentrations of resveratrol potentiates the antiplatelet effect of prostaglandins. Planta Med. 2007;73(5):439–443.
   PubMed Web of Science ®Google Scholar
• Stef G, Csiszar A, Lerea K, et al. Resveratrol inhibits aggregation of platelets from high-risk cardiac patients with aspirin resistance. J Cardiovasc Pharmacol. 2006;48(2):1–5.
   PubMed Web of Science ®Google Scholar
• Olas B, Nowak P, Ponczek M, et al. Resveratrol, a natural phenolic compound may reduce carbonylation proteins induced by peroxynitrite in blood platelets. Gen Physiol Biophys. 2006;25(2):215–222.
   PubMed Web of Science ®Google Scholar
• Olas B, Wachowicz B, Holmsen H, et al. Resveratrol inhibits polyphosphoinositide metabolism in activated platelets. Biochim Biophys Acta. 2005;1714(2):125–133.
   PubMed Web of Science ®Google Scholar
• Toliopoulos IK, Simos YV, Oikonomidis S, et al. Resveratrol diminishes platelet aggregation and increases susceptibility of K562 tumor cells to natural killer cells. Indian J Biochem Biophys. 2013;50(1):14–18.
   PubMed Web of Science ®Google Scholar
• Shen MY, Hsiao G, Liu CL, et al. Inhibitory mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and NO/cyclic GMP. Br J Haematol. 2007;139(3):475–485.
   PubMed Web of Science ®Google Scholar
• Liu J, Pestina TI, Berndt MC, et al. Botrocetin/VWF-induced signaling through GPIb-IX-V produces TxA2 in an alphaIIbbeta3–and aggregation-independent manner. Blood. 2005;106:2750–2756.
   PubMed Web of Science ®Google Scholar
• Nakamura F, Minshall RD, Le Breton GC, et al. Thromboxane A2 mediates the stimulation of inositol 1, 4, 5-trisphosphate production and intracellular calcium mobilization by bradykinin in neonatal rat ventricular cardiomyocytes. Hypertension. 1996;28:444–449.
   PubMed Web of Science ®Google Scholar
• Muzzio M, Huang Z, Hu SC, et al. Determination of resveratrol and its sulfate and glucuronide metabolites in plasma by LC-MS/MS and their pharmacokinetics in dogs. J Pharm Biomed Anal. 2012;59:201–208.
   PubMed Web of Science ®Google Scholar
• Chang CC, Lu WJ, Chiang CW, et al. Potent antiplatelet activity of sesamol in an in vitro and in vivo model: pivotal roles of cyclic AMP and p38 mitogen-activated protein kinase. J Nutr Biochem. 2010;21(12):1214–1221.
   PubMed Web of Science ®Google Scholar
• Chang CC, Lu WJ, Ong ET, et al. A novel role of sesamol in inhibiting NF-κB-mediated signaling in platelet activation. J Biomed Sci. 2011;14:93.
   Web of Science ®Google Scholar
• Thushara RM, Hemshekhar M, Sunitha K, et al. Sesamol induces apoptosis in human platelets via reactive oxygen species-mediated mitochondrial damage. Biochimie. 2013;95(11):2060–2068.
   PubMed Web of Science ®Google Scholar
• Jan KC, Ho CT, Hwang LS. Bioavailability and tissue distribution of sesamol in rat. J Agric Food Chem. 2008;56(16):7032–7037.
   PubMed Web of Science ®Google Scholar
• Thisoda P, Rangkadilok N, Pholphana N, et al. Inhibitory effect of Andrographis paniculata extract and its active diterpenoids on platelet aggregation. Eur J Pharmacol. 2006;553(1–3):39–45.
   PubMed Web of Science ®Google Scholar
• Lu WJ, Lee JJ, Chou DS, et al. A novel role of andrographolide, an NF-kappa B inhibitor, on inhibition of platelet activation: the pivotal mechanisms of endothelial nitric oxide synthase/cyclic GMP. J Mol Med. 2011;89:1261–1273.
   PubMed Web of Science ®Google Scholar
• Lu WJ, Lin KH, Hsu MJ, et al. Suppression of NF-kB signaling by andrographolide with a novel mechanism in human platelets: Regulatory roles of the p38 MAPK-hydroxyl radical-ERK2 cascade. Biochem Pharmacol. 2012;84:914–924.
   PubMed Web of Science ®Google Scholar
• Chen HW, Huang CS, Li CC, et al. Bioavailability of andrographolide and protection against carbon tetrachloride-induced oxidative damage in rats. Toxicol Appl Pharmacol. 2014;280(1):1–9.
   PubMed Web of Science ®Google Scholar
• Panossian A, Hovhannisyan A, Mamikonyan G, et al. Pharmacokinetic and oral bioavailability of andrographolide from Andrographis paniculata fixed combination Kan Jang in rats and human. Phytomedicine. 2000;7(5):351–364.
   PubMed Web of Science ®Google Scholar
• Chuang WY, Kung PH, Kuo CY, et al. Sulforaphane prevents human platelet aggregation through inhibiting the phosphatidylinositol 3-kinase/Akt pathway. Thromb Haemost. 2013;109(6):1120–1130.
   PubMed Web of Science ®Google Scholar
• Jayakumar T, Chen WF, Lu WJ, et al. A novel antithrombotic effect of sulforaphane via activation of platelet adenylate cyclase: ex vivo and in vivo studies. J Nutr Biochem. 2013;24(6):1086–1095.
   PubMed Web of Science ®Google Scholar
• Oh CH, Shin JI, Mo SJ, et al. Antiplatelet activity of L-sulforaphane by regulation of platelet activation factors, glycoprotein IIb/IIIa and thromboxane A2. Blood Coagul Fibrinolysis. 2013;24(5):498–504.
   PubMed Web of Science ®Google Scholar
• Lee YM, Hsieh KH, Lu WJ, et al. Xanthohumol, a Prenylated Flavonoid from Hops (Humuluslupulus), prevents platelet activation in human platelets. Evid Based Complement Alternat Med. 2012;2012:852362.
   PubMed Web of Science ®Google Scholar
• Krenn BM, Gaudernak E, Holzer B, et al. Antiviral activity of the zinc ionophores pyrithione and hinokitiol against picornavirus infections. J Virol. 2009;83(1):58–64.
   PubMed Web of Science ®Google Scholar
• Liu S, Yamauchi H. Hinokitiol a metal chelator derived from natural plants, suppresses cell growth and disrupts androgen receptor signaling in prostate carcinoma cell lines. Biochem Biophys Res Commun. 2006;351:26–32.
   PubMed Web of Science ®Google Scholar
• Lin KH, Kuo JR, Lu WJ, et al. Hinokitiol inhibits platelet activation ex vivo and thrombus formation in vivo. Biochem Pharmacol. 2013;85:1478–1485.
   PubMed Web of Science ®Google Scholar
• Lu WJ, Wu MP, Lin KH, et al. Hinokitiol is a novel glycoprotein VI antagonist on human platelets. Platelets. 2014;25(8):595–602.
   PubMed Web of Science ®Google Scholar
• Cho YM, Hasumura M, Takami S, et al. A 13-week subchronic toxicity study of hinokitiol administered in the diet to F344 rats. Food Chem Toxicol. 2011;49(8):1782–1786.
   PubMed Web of Science ®Google Scholar
• Lu WJ, Chang NC, Jayakumar T, et al. Ex vivo and in vivo studies of CME-1, a novel polysaccharide purified from the mycelia of Cordyceps sinensis that inhibits human platelet activation by activating adenylate cyclase/cyclic AMP. Thromb Res. 2014;134(6):1301–1310.
   PubMed Web of Science ®Google Scholar
• Chang Y, Hsu WH, Lu WJ, et al. Inhibitory mechanisms of CME-1, a novel polysaccharide from the mycelia of Cordyceps sinensis, in platelet activation. Curr Pharm Biotechnol. 2015;16(5):451–461.
   PubMed Web of Science ®Google Scholar
• Sugiura T1, Nakamura H. Metallothionein in platelets. Int Arch Allergy Immunol. 1994;103(4):341–348.
   PubMed Web of Science ®Google Scholar
• Sheu JR, Hsiao G, Shen MY, et al. Inhibitory mechanisms of metallothionein on platelet aggregation in in vitro and platelet plug formation in in vivo experiments. Exp Biol Med. 2003;228:1321–1328.
   Web of Science ®Google Scholar
• Penkowa M, Hidalgo J. Metallothionein I+II expression and their role in experimental autoimmune encephalomyelitis. Glia. 2000;32(3):247–263.
   PubMed Web of Science ®Google Scholar
• Lee YM, Lee JJ, Shen MY, et al. Inhibitory mechanisms of activated matrix metalloproteinase-9 on platelet activation. Eur J Pharmacol. 2006;537:52–58.
   PubMed Web of Science ®Google Scholar
• Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005;115:3339–3347.
   PubMed Web of Science ®Google Scholar
• Lane WJ, Dias S, Hattori K, et al. Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood. 2000;96:4152–4159.
   PubMed Web of Science ®Google Scholar
• Sheu JR, Fong TH, Liu CM, et al. Expression of matrix metalloproteinase-9 in human platelets: regulation of platelet activation in in vitro and in vivo studies. Br J Pharmacol. 2004;143(1):193–201.
   PubMed Web of Science ®Google Scholar
• Lee YM, Lee JJ, Shen MY, et al. Inhibitory mechanisms of activated matrix metalloproteinase-9 on platelet activation. Eur J Pharmacol. 2006;537(1–3):52–58.
   PubMed Web of Science ®Google Scholar
• Papp J, Kenyeres P, Toth K. Clinical importance of antiplatelet drugs in cardiovascular diseases. Clin Hemorheol Microcirc. 2013;53(1–2):81–96.
   PubMed Web of Science ®Google Scholar
• Dobrydneva Y, Weatherman RV, Trebley JP, et al. Tamoxifen stimulates calcium entry into human platelets. J Cardiovasc Pharmacol. 2007;50(4):380–390.
   PubMed Web of Science ®Google Scholar
• Chang Y, Lee JJ, Chen WF, et al. A novel role for tamoxifen in the inhibition of human platelets. Transl Res. 2011;157(2):81–91.
   PubMed Web of Science ®Google Scholar
• Nayak L, Schmaier AH. A platelet acquired storage pool disorder associated with Tamoxifen therapy. Case Rep Hematol. 2012;2012:1–3.
   Google Scholar
• Ramström AS, Fagerberg IH, Lindahl TL. A flow cytometric assay for the study of dense granule storage and release in human platelets. Platelets. 1999;10:153–158.
   PubMed Web of Science ®Google Scholar
• Zhou L, Schmaier AH. Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field. Am J Clin Pathol. 2005;123:172–183.
   PubMed Web of Science ®Google Scholar
• Nanetti L, Camilletti A, Francucci CM, et al. Role of raloxifene on platelet metabolism and plasma lipids. Eur J Clin Invest. 2008;38:117–125.
   PubMed Web of Science ®Google Scholar
• Decensi A, Gandini S, Guerrieri-Gonzaga A, et al. Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women. J Clin Oncol. 1999;17:2633–2638.
   PubMed Web of Science ®Google Scholar
• Decensi A, Robertson C, Rotmensz N, et al. Italian Chemoprevention Group. Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Br J Cancer. 1998;78:572–578.
   PubMed Web of Science ®Google Scholar
• Love RR, Wiebe DA, Feyzi JM, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst. 1994;86:1534–1539.
   PubMed Web of Science ®Google Scholar
• Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J. 2003;24:225–248.
   PubMed Web of Science ®Google Scholar
• Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8:1227–1234.
   PubMed Web of Science ®Google Scholar
• Gaddam V, Li DY, Mehta JL. Anti-thrombotic effects of atorvastatin-an effect unrelated to lipid lowering. J Cardiovasc Pharmacol Ther. 2002;7:247–253.
   PubMedGoogle Scholar
• Ma LP, Nie DN, Hsu SX, et al. Inhibition of platelet aggregation and expression of alpha granule membrane protein 140 and thromboxane B2 with pravastatin therapy for hypercholesterolemia. J Assoc Acad Minor Phys. 2002;13:23–26.
   PubMedGoogle Scholar
• Ali FY, Armstrong PC, Dhanji AR, et al. Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol. 2009;29:706–711.
   PubMed Web of Science ®Google Scholar
• Moscardó A, Vallés J, Latorre A, et al. Reduction of platelet cytosolic phospholipase A2 activity by atorvastatin and simvastatin: biochemical regulatory mechanisms. Thromb Res. 2013;131(4):e154–159.
   PubMed Web of Science ®Google Scholar
• Lee YM, Chen WF, Chou DS, et al. Cyclic nucleotides and mitogen-activated protein kinases: regulation of simvastatin in platelet activation. J Biomed Sci. 2010;17:45.
   PubMed Web of Science ®Google Scholar
• Jayachandran M, Miller VM. Human platelets contain estrogen receptor α, caveolin-1 and estrogen receptor associated proteins. Platelets. 2003;14:75–81.
   PubMed Web of Science ®Google Scholar
• Akarasereenont P, Tripatara P, Chotewuttakorn S, et al. The effects of estrone, estradiol and estriol on platelet aggregation induced by adrenaline and adenosine diphosphate. Platelets. 2006;17(7):441–447.
   PubMed Web of Science ®Google Scholar
• Bar J, Lahav J, Hod M, et al. Regulation of platelet aggregation and adenosine triphosphate release in vitro by 17β-estradiol and medroxyprogesterone acetate in postmenopausal women. Thromb Haemost. 2000;84:695–700.
   PubMed Web of Science ®Google Scholar
• Chen L, Liu Y, Cui B, et al. 17β-estradiol partially attenuates the inhibition of nitric oxide synthase-3 byadvanced glycation end-products in human platelets. Clin Exp Pharmacol Physiol. 2007;34:972–978.
   PubMed Web of Science ®Google Scholar
• Zerr-Fouineau M, Jourdain M, Boesch C, et al. Certain progestins prevent the enhancing effect of 17β-estradiol on NO mediated inhibition of platelet aggregation by endothelial cells. Arterioscler Thromb Vasc Biol. 2009;29:586–593.
   PubMed Web of Science ®Google Scholar
• Moro L, Reineri S, Piranda D, et al. Nongenomic effects of 17 (beta)-estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor (beta) and Src kinase. Blood. 2005;105:115–121.
   PubMed Web of Science ®Google Scholar
• Nakano Y, Oshima T, Matsuura H, et al. Effect of 17β- estradiol on inhibition of platelet aggregation in vitro is mediated by an increase in NO synthesis. Arterioscler Thromb Vasc Biol. 1998;18:961–967.
   PubMed Web of Science ®Google Scholar
• Lu WJ, Lee JJ, Chou DS, et al. Inhibitory signaling of 17β-estradiol in platelet activation: the pivotal role of cyclic AMP-mediated nitric oxide synthase activation. Eur J Pharmacol. 2010;649:140–149.
   PubMed Web of Science ®Google Scholar
• Volterrani M, Rosano G, Coats A, et al. Estrogen acutely increases peripheral blood flow in postmenopausal women. Am J Med. 1995;99:119–122.
   PubMed Web of Science ®Google Scholar
• Vitale C, Mercuro G, Cerquetani E, et al. Time since menopause influences the acute and chronic effect of estrogens on endothelial function. Arterioscler Thromb Vasc Biol. 2008;28:348–352.
   PubMed Web of Science ®Google Scholar
• Haas E, Meyer MR, Schurr U, et al. Differential effects of 17beta-estradiol on function and expression of estrogen receptor alpha, estrogen receptor beta, and GPR30 in arteries and veins of patients with atherosclerosis. Hypertension. 2007;49:1358–1363.
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP, et al. Addition of clopid-ogrel to aspirin in 45,852 patients with acute myocar-dial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607–1621.
   PubMed Web of Science ®Google Scholar
• Herbert JM, Savi P. P2Y12, a new platelet ADP receptor, target of clopidogrel. SeminVasc Med. 2003;3:113–122.
   Google Scholar
• Sofi F, Marcucci R, Gori AM, et al. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost. 2010;103:841–848.
   PubMed Web of Science ®Google Scholar
• Brandt JT, Payne CD, Wiviott SD, et al. A comparison of pra-sugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153:9–16.
   PubMed Web of Science ®Google Scholar
• Montalescot G, Sideris G, Cohen R, et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost. 2010;103:213–223.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Badimon JJ, Saucedo JF, et al. A pharmacodynamic comparison of prasugrel vs. high dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the optimizing anti-platelet therapy in diabetes mellitus (OPTIMUS)-3 Trial. Eur Heart J. 2011;32:838–846.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel com-pared with high loading- and maintenance-dose clopidogrel inpatients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation. 2007;116:2923–2932.
   PubMed Web of Science ®Google Scholar
• Wallentin L. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J. 2009;30:1964–1977.
   PubMed Web of Science ®Google Scholar
• Storey RF, Angiolillo DJ, Patil SB, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (Platelet inhibition and patient outcomes) PLATELET substudy. J Am Coll Cardiol. 2010;56:1456–1462.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel non responders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121:1188–1199.
   PubMed Web of Science ®Google Scholar
• Steiner S, Seidinger D, Huber K, et al. Effect of glycoprotein IIb/IIIa antagonist abciximab on monocyte-platelet aggregates and tissue factor expression. Arterioscler Thromb Vasc Biol. 2003;23:1697–1702.
   PubMed Web of Science ®Google Scholar
• Ibbotson T, McGavin JK, Goa KL. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs. 2003;63:1121–1163.
   PubMed Web of Science ®Google Scholar
• Braunwald’s heart disease: a textbook of cardiovascular medicine. 9th ed. Philadelphia: Elsevier Saunders; 2012.
   Google Scholar
• Hamilton J. Protease-activated receptors as targets for antiplatelet therapy. Blood Rev. 2009;23:61–65.
   PubMed Web of Science ®Google Scholar
• Kakkos SK, Nicolaides AN. S-18886 Servier. Curr Opin Investig Drugs. 2002;3:1324–1327.
   PubMedGoogle Scholar
• Shalito I, Kopyleva O, Serebruany V. Novel antiplatelet agents in development: prasugrel, ticagrelor, and cangrelor and beyond. Am J Ther. 2009;16:451–458.
   PubMed Web of Science ®Google Scholar